Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Maria Patti

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Endocrine Connections|May 2, 2018
Metabolic disorders during pregnancy and postpartum cardiometabolic riskAngelo Maria Patti, Kalliopi Pafili, Nikolaos Papanas, et al.
Expert Review of Endocrinology & Metabolism|February 14, 2019
Oxidative stress and small, dense low-density lipoproteins: current and future perspectivesAli A Rizvi, Giuseppe Montalto, Angelo Maria Patti, et al.
Expert Opinion on Pharmacotherapy|March 30, 2019
Advances in pharmacological treatment of type 1 diabetes during pregnancyAngelo Maria Patti, Rosaria Vincenza Giglio, Kalliopi Pafili, et al.
Angiology|July 20, 2014
Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosanAngelo Maria Patti, Niki Katsiki, Dragana Nikolic, et al.
Expert Opinion on Pharmacotherapy|August 24, 2018
Pharmacotherapy for gestational diabetesAngelo Maria Patti, Rosaria Vincenza Giglio, Kalliopi Pafili, et al.
Expert Opinion on Pharmacotherapy|February 3, 2011
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?Manfredi Rizzo, Egle Corrado, Angelo Maria Patti, et al.
Expert Review of Clinical Pharmacology|January 16, 2019
Future perspectives of the pharmacological management of diabetic dyslipidemiaAngelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, et al.
Current Pharmaceutical Design|December 11, 2013
Incretin-based therapies, glucometabolic health and endovascular inflammationManfredi Rizzo, Dragana Nikolic, Maciej Banach, et al.
Metabolism: Clinical and Experimental|June 20, 2020
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetesAnca Pantea Stoian, Alexandros Sachinidis, Roxana Adriana Stoica, et al.
Journal of Clinical Medicine|April 1, 2020
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 DiabetesAngelo Maria Patti, Ali A Rizvi, Rosaria Vincenza Giglio, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Endocrine Connections|May 2, 2018
Metabolic disorders during pregnancy and postpartum cardiometabolic riskAngelo Maria Patti, Kalliopi Pafili, Nikolaos Papanas, et al.
Expert Review of Endocrinology & Metabolism|February 14, 2019
Oxidative stress and small, dense low-density lipoproteins: current and future perspectivesAli A Rizvi, Giuseppe Montalto, Angelo Maria Patti, et al.
Expert Opinion on Pharmacotherapy|March 30, 2019
Advances in pharmacological treatment of type 1 diabetes during pregnancyAngelo Maria Patti, Rosaria Vincenza Giglio, Kalliopi Pafili, et al.
Angiology|July 20, 2014
Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosanAngelo Maria Patti, Niki Katsiki, Dragana Nikolic, et al.
Expert Opinion on Pharmacotherapy|August 24, 2018
Pharmacotherapy for gestational diabetesAngelo Maria Patti, Rosaria Vincenza Giglio, Kalliopi Pafili, et al.
Expert Opinion on Pharmacotherapy|February 3, 2011
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?Manfredi Rizzo, Egle Corrado, Angelo Maria Patti, et al.
Expert Review of Clinical Pharmacology|January 16, 2019
Future perspectives of the pharmacological management of diabetic dyslipidemiaAngelo Maria Patti, Rosaria Vincenza Giglio, Nikolaos Papanas, et al.
Current Pharmaceutical Design|December 11, 2013
Incretin-based therapies, glucometabolic health and endovascular inflammationManfredi Rizzo, Dragana Nikolic, Maciej Banach, et al.
Metabolism: Clinical and Experimental|June 20, 2020
The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetesAnca Pantea Stoian, Alexandros Sachinidis, Roxana Adriana Stoica, et al.
Journal of Clinical Medicine|April 1, 2020
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 DiabetesAngelo Maria Patti, Ali A Rizvi, Rosaria Vincenza Giglio, et al.
Pageof 5